Karyopharm Therapeutics Inc.
For the period ended Mar 31, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 14, 2026
KPTI$0.02-56.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Deficit
| Common Shares · AdditionalPaid-InCapital · AccumulatedOtherComprehensive (Loss)Income · AccumulatedDeficit · TotalStockholders’Deficit | ||||||
|---|---|---|---|---|---|---|
| Shares · Amount | ||||||
| Balance as of December 31, 2025 | 18,311 | $14 | $1,466,488 | $71 | $(1,759,499) | $(292,926) |
| Vesting of restricted stock | 209 | — | — | — | — | — |
| Issuance of common stock under Open Market Sale Agreement, net of issuance costs | 2,994 | — | 19,827 | — | — | 19,827 |
| Issuance of common stock and warrants in private placement offering, net of issuance costs | 1,030 | — | 26,866 | — | — | 26,866 |
| Stock-based compensation | — | — | 3,007 | — | — | 3,007 |
| Unrealized loss on investments | — | — | — | (3) | — | (3) |
| Foreign currency cumulative translation adjustment | — | — | — | (25) | — | (25) |
| Net loss | — | — | — | — | (22,392) | (22,392) |
| Balance as of March 31, 2026 | 22,544 | $14 | $1,516,188 | $43 | $(1,781,891) | $(265,646) |
| Balance as of December 31, 2024 | 8,413 | $13 | $1,377,786 | $(356) | $(1,563,460) | $(186,017) |
| Vesting of restricted stock | 155 | — | — | — | — | — |
| Stock-based compensation | — | — | 3,560 | — | — | 3,560 |
| Unrealized loss on investments | — | — | — | (26) | — | (26) |
| Foreign currency cumulative translation adjustment | — | — | — | 61 | — | 61 |
| Net loss | — | — | — | — | (23,462) | (23,462) |
| Balance as of March 31, 2025 | 8,568 | $13 | $1,381,346 | $(321) | $(1,586,922) | $(205,884) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.